Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Pharmaceutical giant Biogen Inc. is expanding its relationship with BioMotiv LLC of Shaker Heights and plans to invest another $10 million in the therapeutic accelerator company associated with The Harrington Project for Discovery & Development at University Hospitals.
BioMotiv announced in a news release on Tuesday, Sept. 6, that its strategic partnership with Cambridge, Mass.-based Biogen now includes the ophthalmology therapeutic area, in addition to an existing neurology partnership.
Click here to read the complete article.
Originally published September 6, 2016.